Compass Pathways files FDA application for psilocybin treatment
A Decade of Research Pays Off
London-based Compass Pathways submitted a New Drug Application to the U. S. Food and Drug Administration on Monday. The filing covers COMP360, a psilocybin formulation designed for treatment-resistant depression. This marks a critical milestone for the company.
The move positions Compass ahead of competing biotechs in the psychedelic drug race. Usona and other rivals are also advancing similar compounds. The NDA submission signals that psilocybin therapies are nearing regulatory review.
Compass Pathways emerged from a nonprofit research initiative. It went public on Nasdaq in September 2020. The company has spent years developing COMP360 for patients who have not responded to standard antidepressants.
What Does This Mean for Patients?
The NDA includes clinical trial data demonstrating efficacy and safety. FDA will now evaluate the submission. Approval would make COMP360 the first psilocybin product cleared for treatment-resistant depression in the U. S. market.
For the roughly 30% of depression patients who do not respond to conventional medication, a new option is emerging. Psilocybin-assisted therapy combines the compound with structured psychological support.
Compass Pathways expects FDA to complete its review within the standard 10-month window. A positive decision could lead to a 2025 launch. Competitors like Usona are filing or preparing their own NDAs.
Frequently Asked Questions
What is COMP360? COMP360 is a psilocybin formulation developed by Compass Pathways. It is designed for patients with treatment-resistant major depressive disorder.
When will the FDA decide? The FDA typically reviews NDAs within 10 months. Compass Pathways expects a decision by mid-2025.
Who else is competing in this space? Usona and other biotechs are advancing psilocybin candidates. The market is becoming crowded as multiple firms target the same unmet need.